Genpharmasec Ltd. Approves Unaudited Standalone & Consolidated Financial Results for Q3 2025

Genpharmasec Ltd. announced the approval of its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025, at a Board of Directors meeting held on February 09, 2026. The review of the financial results was conducted by Bilimoria Mehta & Co. Chartered Accountants, who found no material misstatements. The company is primarily engaged in a single business segment and has reclassified certain equity shares from Inventories to Financial Investments in accordance with Ind AS 109 and Ind AS 8.